ACXP Acurx Pharmaceuticals Inc.

FDA Catalyst Company
2.76
+0.06  (+2%)
Previous Close 2.7
Open 2.88
52 Week Low 2.61
52 Week High 8.74
Market Cap $28,317,201
Shares 10,263,202
Float 7,867,001
Enterprise Value $25,251,507
Volume 2,497
Av. Daily Volume 19,432
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
Maxim Group Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 11/29/2021

Latest News

  1. STATEN ISLAND, N.Y., May 11, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the quarter ended March 31, 2022. 

    Highlights of, and certain events subsequent to, the first quarter of 2022 include:

    • Enrollment continues in the Company's ongoing Phase 2b clinical trial of patients with C. difficile Infection (CDI) with anticipated completion of enrollment late in the second half of 2022;
    • Based on the strength of our previously reported Phase 2a results (100% cure rate at end of treatment with no recurrences at Day 38 follow…
    View Full Article
  2. STATEN ISLAND, N.Y., April 29, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will release its 2022 first quarter financial results on Wednesday, May 11 2022, at 8:30 am ET before the U.S. financial markets open.

    David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:


    Date:

    Wednesday, May 11, 2022


    Time:

    8:30 a.m. ET


    Toll free (U.S.):

    877-790-1503


    International:

    Click here for participant international Toll-Free

    View Full Article
  3. STATEN ISLAND, N.Y., March 17, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the fourth quarter and full year ended December 31, 2021. 

    Highlights of the fourth quarter and full year ended December 31, 2021 include:

    • Acurx is currently enrolling patients in a Phase 2b clinical trial, which will include up to 16 U.S. sites, in patients with C. difficile infection (CDI) with enrollment expected to be completed in the second half of 2022;
    • The Phase 2b clinical trial will compare the efficacy of oral ibezapolstat, the…
    View Full Article
  4. STATEN ISLAND, N.Y., March 16, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that Company's President & CEO, David P. Luci, has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT.

    Mr. Luci will be presenting during the Fireside Chat with Acurx Pharmaceuticals, Inc. at 9:30 am ET on Monday, March 28, 2022.

    During this virtual conference, investors will hear from executives from a wide range of sectors including Biotech, Clean Energy, Electric Vehicles…

    View Full Article
  5. STATEN ISLAND, N.Y., March 7, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will release its fourth quarter 2021 and fiscal year end 2021 financial results on Thursday, March 17, 2022, at 8:30 am ET before the U.S. financial markets open.

    David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:

    Date: Thursday, March 17, 2022

    Time: 8:30 a.m. ET

    Toll free (U.S. and International): 877-790-1503

    Conference ID…

    View Full Article
View All Acurx Pharmaceuticals Inc. News